William Blair started coverage on shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) in a research note published on Tuesday, October 17th, MarketBeat.com reports. The firm issued an outperform rating and a $35.00 target price on the biotechnology company’s stock. William Blair also issued estimates for Audentes Therapeutics’ Q3 2017 earnings at ($0.91) EPS, Q4 2017 earnings at ($0.80) EPS, FY2017 earnings at ($3.40) EPS, FY2018 earnings at ($3.44) EPS, FY2019 earnings at ($3.69) EPS, FY2020 earnings at ($3.58) EPS and FY2021 earnings at ($3.61) EPS.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Audentes Therapeutics from a hold rating to a buy rating and set a $23.00 price target for the company in a research report on Monday, July 17th. Bank of America Corporation reiterated a buy rating and set a $33.00 target price (up previously from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. ValuEngine upgraded shares of Audentes Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 24th. Raymond James Financial, Inc. began coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They set a market perform rating for the company. Finally, Evercore ISI began coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an outperform rating and a $23.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $25.71.
Audentes Therapeutics (NASDAQ:BOLD) traded up $0.38 on Tuesday, reaching $25.40. 81,971 shares of the company’s stock traded hands, compared to its average volume of 252,329. Audentes Therapeutics has a 1 year low of $13.13 and a 1 year high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.10). equities analysts forecast that Audentes Therapeutics will post -3.53 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “William Blair Begins Coverage on Audentes Therapeutics, Inc. (BOLD)” was originally reported by BBNS and is the property of of BBNS. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/audentes-therapeutics-inc-bold-receives-new-coverage-from-analysts-at-william-blair/1721853.html.
In other news, SVP Mary Newman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the transaction, the senior vice president now owns 10,000 shares in the company, valued at $200,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $27.92, for a total transaction of $698,000.00. The disclosure for this sale can be found here. Insiders have sold 766,500 shares of company stock worth $21,443,730 over the last three months. Insiders own 47.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. bought a new stake in Audentes Therapeutics in the second quarter valued at $2,870,000. Schwab Charles Investment Management Inc. boosted its holdings in Audentes Therapeutics by 139.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock valued at $490,000 after acquiring an additional 14,900 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 5,700 shares in the last quarter. Ardsley Advisory Partners boosted its holdings in shares of Audentes Therapeutics by 59.7% during the 2nd quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock valued at $384,000 after buying an additional 7,500 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Audentes Therapeutics during the 2nd quarter valued at $252,000. Institutional investors and hedge funds own 77.07% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with our FREE daily email newsletter.